Press Releases

Drug developers in APAC have typically faced many challenges when it comes to preclinical development, from limited access to animal model providers and poor service offering breadth and capacity, to a scarcity of comprehensive, one-stop-shop preclinical partners. What’s more, mouse model providers in the region may not have the standardized, well-recognized model sets used in international research, making results comparison difficult.

The partnership between TransCure bioServices and Preclina directly addresses these challenges, providing APAC customers with the full suite of advanced preclinical services under one umbrella, as well as the most advanced, internationally recognized mouse models and cell lines to help optimize and streamline their preclinical programs.

"TransCure’s one-stop-shop offering spans three platforms, more than 50 proven animal models, and a vast selection of technical services," said Kiave Ho Wang Yin, PhD, Chief Business Officer at TransCure bioServices. "By joining forces with Preclina, we further bolster those offerings with extensive autoimmune and inflammatory disease expertise, unlocking new insights for APAC-based developers, while bringing our renowned partnership-rather-than-supplier approach to the region. With this foothold, we’re uniquely positioned to grow our capacity in the region and further innovate for the benefit of our sponsors."

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders, such as NASH, fibrosis, arthritis, and scleroderma. It boasts extensive knowledge in immunology, with expertise in patient-derived cells and animal models that faithfully recapitulate these disorders. Their fully integrated drug discovery platform has made them an indispensable partner for APAC clients developing novel drugs and diagnostic and treatment technologies.

"Combining our know-how and services with TransCure’s offers a unique opportunity to better address the preclinical needs of APAC customers," said Young Mo Kang, PhD, CEO at Preclina. "We’re delighted that this partnership will further augment the high-quality, comprehensive services we’re well known for. We look forward to delivering the fruits of this collaboration to our customers, helping them carve a smoother route to better preclinical research for transformative therapeutics and diagnostics."

For more information about TransCure bioServices, please visit: https://transcurebioservices.com/

To find out more about Preclina Inc., please visit: https://www.preclina.com/